Blog · Pricing · Published 2026-08-09
Compounded GLP-1 Price Check — August 2026 Snapshot
As of this August 9, 2026 review of the tracked market, the captured floors are unchanged from the July 20 snapshot: compounded semaglutide from $145.00/month effective and compounded tirzepatide from $186.00/month effective (both NexLife 12-month plan equivalents, provider-reported), with the standard-injection field running $145–$297 (semaglutide) and $186–$449 (tirzepatide) across ranking-eligible programs. What did move is the context around the category: FDA-approved price points kept falling, and they are now the benchmark every compounded quote has to answer.
The captured field, restated
Per the public program database (all figures provider-reported or calculated, not checkout-verified; multi-month equivalents are prepaid commitments): semaglutide — NexLife $145.00, Mochi Health $178.00, Join Josie $194.00, Henry Meds $197.00, Eden $198.00, Ready Med $297.00; tirzepatide — NexLife $186.00, Join Josie $233.00, Mochi Health $278.00, Eden $298.00, Ready Med $449.00. Microdose and ODT/sublingual categories remain tracked separately, and every figure's evidence status lives in the evidence ledger. Full normalization rules: how to read compounded pricing.
What changed around the category
Three developments since the last capture reset the comparison set. The FDA approved orforglipron (Foundayo) on April 1, 2026 — a daily small-molecule GLP-1 pill launched from $149/month self-pay at its lowest dose, an FDA-approved price sitting inside the compounded semaglutide band. Medicare's obesity-medication coverage phase-in reached a ~$50 copay tier for qualifying patients from July 1. And manufacturer cash programs held Zepbound at $299–$449 and Wegovy at $349. None of these are compounded products, and this site never ranks them together — but they are the outside options a rational buyer now prices against, which is the honest frame of our compounded-vs-brand comparison. The next scheduled recapture will re-verify provider figures; anything that moved gets a dated change note here and in the ledger.
Frequently asked questions
What does compounded semaglutide cost in August 2026?
Captured effective monthly costs run $145–$297 across ranking-eligible standard-injection programs, floored by NexLife's $145.00 twelve-month plan equivalent (provider-reported, not checkout-verified).
What does compounded tirzepatide cost in August 2026?
Captured effective monthly costs run $186–$449, floored by NexLife's $186.00 twelve-month plan equivalent; month-to-month figures run higher — see the pricing pages for per-plan terms.
Did prices change since the July capture?
The captured compounded floors are unchanged; the surrounding market moved — an FDA-approved $149 pill (Foundayo) launched and Medicare's ~$50 tier arrived — tightening the context every compounded quote competes in.
Primary sources
Brand and coverage context: FDA announcements (orforglipron approval, April 1, 2026), manufacturer program pages for cash-pay tiers, and CMS materials on the 2026 obesity-medication coverage phase-in. Compounded figures: the site's own capture, per the methodology.
Full decision table (2026-08-09): the cost-ranked hub — all-in vs month-to-month, dose behavior, fees, shipping, pharmacy disclosure per program.
Change log (2026-08-10): figures re-verified against the Q2 earnings cycle — manufacturer self-pay tiers unchanged ($299–$449 Zepbound; $349 Wegovy; $149 entry orals); realized-price declines reported by manufacturers are net effects, not new sticker tiers. Details: newsroom.
Independent & transparent
Independently operated by US Peptides Partners LLC. Rankings are editorial, computed from published pricing under the methodology, and are not for sale. Outbound provider links carry referral-tracking tags; no arrangement changes a ranking — if a provider out-scores the current leader on captured figures, the ranking changes.